Neuroendocrine and Aggressive-Variant Prostate Cancer

Area of Science:

• Oncology
• Urology
• Cancer Biology

Background:

• Neuroendocrine (NE) differentiation in prostate cancer can arise de novo or secondary to hormonal therapy in castration-resistant prostate cancer (CRPC).
• This NE phenotype is associated with aggressive clinical behavior, resistance to hormonal therapies, and poor prognosis.
• A subset of CRPC patients displays aggressive-variant prostate cancer (AVPC) with clinical and molecular similarities to small-cell prostate cancer (SCPC), despite lacking NE differentiation.

Purpose of the Study:

• To provide an overview of current knowledge on prostate cancer with NE differentiation and AVPC.
• To focus on the clinical characteristics and management of these aggressive prostate cancer subtypes.
• To discuss available and experimental therapeutic strategies for NEPC and AVPC.

Main Methods:

• Literature review of studies on neuroendocrine prostate cancer and aggressive-variant prostate cancer.
• Analysis of clinical characteristics, molecular features, and treatment responses.
• Synthesis of information on current and emerging therapeutic approaches.

Main Results:

• NEPC and AVPC exhibit aggressive clinical courses and poor prognoses.
• Both subtypes share sensitivity to platinum-based chemotherapy, but with limited clinical benefit.
• Optimal treatment strategies for AVPC remain largely undefined, necessitating further research.

Conclusions:

• Understanding the biology of NEPC and AVPC is crucial for developing effective treatments.
• Current research focuses on improving therapeutic outcomes for patients with these aggressive prostate cancer variants.
• Further investigation into novel therapeutic strategies is warranted for NEPC and AVPC.